High dose rifampin for 2 months vs standard dose rifampin for 4 months, to treat TB infection: Protocol of a 3-arm randomized trial (2R2).
Federica Fregonese, Lika Apriani, Leila Barss...
https://pubmed.ncbi.nlm.nih.gov/36730240/Actively Recruiting
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2026-05-11
1800
Participants Needed
14
Research Sites
113 weeks
Total Duration
Researchers are evaluating shorter and safer treatment regimens for latent Tuberculosis Infection TB using an adaptive Phase 2 randomized open-label trial design. The study aims to compare the safety, completion, and tolerability of at least three new daily self-administered Tuberculosis Preventive Treatment TPT regimens against the standard 4 months of Rifampin at 10 mgkgday 4R10 in adults and children aged 5 years and older. The goal is to identify regimens lasting two months or less that are not inferior in safety and adherence to the standard treatment, with plans to test the best regimen further in a Phase 3 trial. The trial begins with three treatment groups the standard 4R10 rifampin regimen, 2 months of Rifampin at 20 mgkgday 2R20, and 1 month of daily levofloxacin and rifapentine 1LP. If either experimental regimen fails to meet safety and tolerability criteria, it may be dropped and replaced by another new 1-2 month regimen, such as 1 month of Isoniazid plus rifapentine 1HP. Participants are randomized and monitored closely, with visits scheduled at 2 weeks, during treatment, and after completion. Safety evaluations include clinical assessments, blood tests, and pharmacokinetic sampling. Participants may switch to the standard regimen if intolerability symptoms occur. During the study, participants complete symptom questionnaires, pill counts, and telephone follow-ups to monitor adherence and side effects. After treatment, they are contacted every 3 months for up to 26 months to check for signs of active TB. The primary outcome is the occurrence of severe treatment-related adverse events from the start of treatment until two weeks after completion. Secondary outcomes include treatment completion rates, tolerability, patient preferences, drug exposure, costs, and incidence of active TB. Safety analyses will be regularly conducted to ensure participant well-being throughout the trial.
CONDITIONS
Shorter and Safer Treatment Regimens for Latent TB
D
Dick Menzies, MD
C
Chantal Valiquette
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 to 4 months depending on regimen
Participants receive one of three experimental Tuberculosis Preventive Treatment regimens: 4 months of rifampin at 10 mg/kg/day, 2 months of rifampin at 20 mg/kg/day, or 1 month of levofloxacin and rifapentine. Treatment includes self-administered daily doses with safety and tolerability monitoring.
Participants in the 4-month rifampin arm have in-person visits at 2 weeks and at treatment end, plus telephone calls at 4, 8, and 12-13 weeks. Participants in the 2-month rifampin arm have in-person visits at 2 weeks and at treatment end (8-9 weeks). Participants in the 1-month levofloxacin and rifapentine arm have in-person visits at 2 weeks and at treatment end (4 weeks).
Duration - Up to 26 months post-randomization
Participants are contacted every 3 months for up to 26 months after randomization to monitor for symptoms of active tuberculosis and any hospitalizations. Suspected active tuberculosis cases will be investigated, and TB disease notifications cross-checked with local registries.
Quarterly contacts (telephone or in-person) every 3 months
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Federica Fregonese, Lika Apriani, Leila Barss...
https://pubmed.ncbi.nlm.nih.gov/36730240/Fajri Gafar, Vycke Yunivita, Federica Fregonese...
https://pubmed.ncbi.nlm.nih.gov/38750674/McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor